TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06515470: Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer

Sponsor: Biotheryx, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 82 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$5,152,224

Rescue Site Savings

+$3,392,928

Unlock Full NCT06515470 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06515470 Rescue Dossier →